NYSE:NUVBPharmaceuticals
Nuvation Bio Cancer Data Update Tests Valuation Gap After Share Pullback
Nuvation Bio (NYSE:NUVB) presented nearly one additional year of follow up data from the TRUST-I and TRUST-II studies of IBTROZI (taletrectinib) at the AACR Annual Meeting 2026.
The new data focus on long term efficacy and safety in ROS1 positive non small cell lung cancer, including both treatment naïve and previously treated patients.
This update builds on IBTROZI's existing FDA approval and adds fresh clinical detail that has not been reflected in recent coverage of the company.
Nuvation...